External validation of the new prognostic western score in predicting survival after curative resection of gastric cancer

Abstract

Aim: Gastric cancers may progress differently depending on the factors affecting the prognosis. In our study, we evaluated the external validation of the new prognostic western score used to predict the surveillance of gastric cancer patients undergoing curative resection.
 Material and methods: The study included 139 patients over 18 years of age who underwent curative resection for gastric adenocarcinoma in our hospital between 2004 and 2015. The demographic characteristics of the patients and their albumin level, neutrophil lymphocyte ratio and pathological tumor-nodes-metastasis stage were evaluated.
 Results: Fifty-nine (42.4%) of the patients were female and 80 (57.6%) were male. The mean albumin value was 39±7 mg/L, and the median value of the neutrophil/lymphocyte ratio was 2.5 (1.76-4). According to the pathological tumor-nodes-metastasis staging, 13 cases (9.4%) were stage 1, 21 (15.1%) stage 2, 99 (71.2%) stage 3, and 6 (4.3%) stage 4. The five-year median survival of the patients was 32.5 months. Age was significantly higher in the mortality group (P=.021). In the log-rank analysis, a low albumin level, a high neutrophil lymphocyte ratio, and a high tumor-nodes-metastasis stage were statistically significant in the mortality group (P=.001, .000 and .030 respectively). In the Cox regression analysis, the only significant variable was determined as pathological stage (P=.005).
 Conclusion: The new prognostic western score was not significant in predicting the prognosis of gastric cancers.